ASCLEPIOS BIOSEARCH
ASCLEPIOS BIOSEARCH
Founded:
2009-01-01
Status:
Closed
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving OpenResty AdBlock Acceptable Ads
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2012-09-26 | Genmedica Therapeutics | Asclepios Biosearch investment in Venture Round - Genmedica Therapeutics | 12 M EUR |
More informations about "Asclepios Biosearch"
Asclepios Biosearch - Crunchbase Investor Profile & Investments
Genmedica Therapeutics raised €12,000,000 / Series Unknown from Asclepios Biosearch. Discover more funding rounds . Details. Edit Details Section. Headquarters Regions Europe, …See details»
Asclepios Biosearch - Investments, Portfolio & Company Exits
Asclepios Biosearch has invested in Genmedica Therapeutics on Sep 26, 2012. This investment - Venture Round - Genmedica Therapeutics - was valued at . obfuscated. obfuscated. How …See details»
Asclepios Bioresearch Investor Profile: Portfolio & Exits - PitchBook
Asclepios Bioresearch's latest investment was on 21-Feb-2023 in Tribun Health, a company within the Diagnostic Equipment industry. Data Transparency. Meet our data hygiene team. …See details»
Asclepios Bioresearch - Company Profile & Staff Directory
Medical and pharma financier specialising in medical research. Managing down its investments after successfully funding trials in pharma and biotech spanning wound healing, type 2 …See details»
Asclepios Bioresearch and Genmedica Sign Clinical Stage …
Asclepios Bioresearch (UK) Ltd entered into an agreement with Genmedica Therapeutics S.L. that secures 12m€ of financing sufficient to complete phase 1 and phase 2 clinical development of …See details»
Asclepios Biosearch - Tech Stack, Apps, Patents & Trademarks
Asclepios Biosearch was founded in 2009. Start Free Trial . Chrome ExtensionSee details»
Asclepios Biosearch - Company Profiles - BCIQ
For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, …See details»
Asclepios Biosearch — 1 Investments, Portfolio, Team members — …
Asclepios Biosearch is the famous Corporate Investor, which was founded in 2009. The main department of described Corporate Investor is located in the London. The fund was located in …See details»
Asclepios Bioresearch Ltd. - BioCentury Company Profiles - BCIQ
Nov 19, 2012 Asclepios Bioresearch Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
Asclepios – A student-led space mission analog …
Imagined in August 2019, Asclepios was born as a Space@yourService initiative project, which aims at organizing a student-led space analogue mission simulating a mission on another celestial body. It is the first initiative worldwide …See details»
Asclepios: a research project team at INRIA for the analysis and ...
Asclepios is the name of a research project team officially launched on November 1st, 2005 at INRIA Sophia-Antipolis, to study the Analysis and Simulation of Biological and Medical …See details»
Biosearch Technologies - Wikidata
Biotech company, expert in oligonucleotide design and manufacturing. This page was last edited on 8 November 2024, at 00:47. All structured data from the main, Property, Lexeme, and …See details»
Call For Projects – Asclepios
This call for projects aims to enable space-related projects and experiments to be integrated into the Asclepios V lunar analogue mission. Key research areas include life sciences, space …See details»
The Astronauts - Asclepios
This team is composed of the nine members of the astronaut crew. The crew will perform an analogue space mission in all its components: training and thorough preparation; maintain and …See details»
Novartis announces NEJM publication of Phase III ASCLEPIOS trials ...
Aug 5, 2020 It significantly reduced the mean number of both Gd+ T1 lesions (97% and 94% relative reduction in ASCLEPIOS I and II, respectively, both P<.001) and new or enlarging T2 …See details»
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ...
Sep 13, 2019 The ASCLEPIOS I and II studies are twin, identical design, flexible duration (up to 30 months), double-blind, randomized, multi-center Phase III studies evaluating the safety and …See details»
Novartis announces NEJM publication of Phase III ASCLEPIOS trials ...
The ASCLEPIOS I and II studies enrolled 1882 patients with MS, between the ages of 18 and 55 years, with an Expanded Disability Status Scale (EDSS) score between 0 and 5.5. 1 The …See details»
Novartis announces NEJM publication of Phase III ASCLEPIOS
Aug 5, 2020 Showed significant reduction of both gadolinium enhancing (Gd+) T1 lesions with a 97% and 94% relative reduction in ASCLEPIOS I and II, respectively, (both P<.001), and an …See details»
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Aug 5, 2020 In ASCLEPIOS I, the mean number of new or enlarging lesions per year on T2-weighted MRI was 0.72 with ofatumumab and 4.00 with teriflunomide (82% lower number of …See details»
Asclepieia in ancient Greece: pilgrimage and healing ... - PubMed
Mar 1, 2024 Asclepios, the first physician-demigod in Greek mythology, was born in Thessaly of the God Apollo and Coronis, a mortal mother. ... 2 Directorate of Research, Studies, and …See details»